Investor Relations
Corporate Profile
The cancer treatment paradigm has shifted dramatically, providing evidence that the immune system can be educated to recognize and eliminate the patient’s tumor cells. At Candel Therapeutics, we are developing viral immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor antigens and neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor through in situ vaccination, with the potential to change disease outcomes across a variety of indications. Candel’s product candidates are designed to improve survival while maintaining quality of life in patients with early- to late-stage disease.
NASDAQ: CADL
| Last Price | $5.90 |
|---|---|
| Change | +0.06 (+1.03%) |
| Volume | 256,180 |
| 52 Week High | $13.68 |
| 52 Week Low | $4.25 |
| Feb 2, 2026 1:34 PM EST | |
Minimum 15 minutes delayed. Source: LSEG
News Releases
Events
Dec 5, 2025 at 11:00 AM EST
Candel Therapeutics to Host Virtual R&D Event
Nov 18, 2025 at 8:00 AM GMT
Jefferies Global Healthcare Conference in London
Aug 13, 2025 at 2:00 PM EDT
CG 45th Annual Growth Conference
